Abstract：Objective：To discuss the mechanism of Polygonati Rhizoma in treating chloasma based on network pharmacology and molecular docking. Methods： Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) was retrieved to screen for active ingredients related to Polygonati Rhizoma， and SwissTargetPrediction was used to predict the target action of effective ingredients. The disease targets related to chloasma were collected through the GeneCard， Drugbank database， and the potential effective targets for the treatment of chloasma by intersecting effective ingredient targets and disease targets were obtained through Venn diagrams. A network diagram of active ingredients and potential effective targets was drawn， and Cytoscape software was used to analyze the importance of each active ingredient in the treatment of chloasma. The STRING database was used to analyze protein-protein interactions between the intersection targets of Polygonati Rhizoma and diseases， and the key targets of Polygonati Rhizoma in the treatment of chloasma were screened. The David database was performed to conduct the enrichment analysis on intersection targets on Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway，and the main active ingredients and target proteins of Polygonati Rhizoma were deeply explored. The molecular binding energy between the active ingredients and target proteins was verified through molecular docking. Results： A total of 12 active ingredients of Polygonati Rhizoma were selected， and 327 targets of Polygonati Rhizoma for chloasma were identified. The core active ingredients of Polygonati Rhizoma in treating chloasma included (2R) -7-hydroxy-2- (4-hydroxyphenyl) -4-phenylpropanedihydrofuran， glycyrrhizin， 4，5-dihydroxyflavones， scutellarin， sitosterol， sibiricoside A， and Zhonghualiaoine 1， β -sitosterol， and the core targets included cyclin A2 (CCNA2)， cyclin A1 (CCNA1)， cyclin B1 (CCNB1)， cyclin E1 (CCNE1)， cyclin dependent kinase 2 (CDK2)， and aurora kinase A (AURKA). The pathway of Polygonati Rhizoma in treating chloasma was mainly enriched in progesterone mediated signaling pathways such as oocyte maturation， cell aging， hepatitis B， and cancer. Molecular docking revealed strong binding affinity between active ingredients and targets. Conclusion： Polygonati Rhizoma may act on targets such as CCNA2，CCNE1，CDK2，CCNA1，and CCNA1 through components such as (2R) -7- hydroxy-2- (4-hydroxyphenyl) -4-phenylpropanedihydrofuran，glycyrrhizin，and 4，5-dihydroxyflavones， and treat chloasma by regulating progesterone mediated signaling pathways such as oocyte maturation， cell aging，and hepatitis B.